Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A real-world study finds talquetamab (Talvey) delivers similar response rates in relapsed/refractory multiple myeloma patients regardless of whether they'd have qualified for the MonumenTAL-1 trial. Surprisingly, trial-ineligible patients — the vast majority in routine practice — showed longer PFS and OS. The findings suggest the drug's benefit extends well beyond its registrational trial population.
A retrospective analysis from Moffitt Cancer Center found that talquetamab (Talvey), a bispecific T-cell engager approved for heavily pretreated multiple myeloma, performs similarly in real-world patients regardless of whether they would have met the eligibility criteria of the MonumenTAL-1 trial. Crucially, 85.3% of the 95 patients treated in routine practice would have been excluded from that registrational trial — most commonly due to prior BCMA-directed or T-cell redirecting therapy.
Overall response rates (ORR) were comparable between trial-eligible and trial-ineligible groups. Unexpectedly, trial-ineligible patients showed longer median progression-free survival (18.2 vs. 9.1 months) and overall survival (22.5 vs. 11.2 months) — though investigators caution these differences are hypothesis-generating given potential selection bias.
Why it matters: As T-cell redirecting therapies move earlier in the treatment course, understanding how talquetamab performs in broader, real-world populations — including those with prior BCMA exposure — is critical for guiding sequencing decisions in relapsed/refractory myeloma.
